- +1 858 909 0079
- +1 858 909 0057
- [email protected]
- +1 858 909 0079
- [email protected]
Cat# | Product Name | Swiss Prot# | Size | Price (US$) | Order |
PN0435 | Recombinant Protein-Feline leukemia virus Envelope protein (a.a.51 to 565) | A8W3S2 | 100 µg | 1195 | |
PN0436 | Recombinant Protein-Feline leukemia virus virion core structural peptide p15 (a.a.75 to 201) | O89811 | 100 µg | 1195 | |
PN0437 | Recombinant Protein-Feline leukemia virus virion core structural peptide p12 (a.a.202 to 271) | O89811 | 100 µg | 1195 | |
PN0438 | Recombinant Protein-Feline leukemia virus virion core structural peptide p27 (a.a.272 to 519) | O89811 | 100 µg | 1195 | |
PN0439 | Recombinant Protein-Feline leukemia virus virion core structural peptide p10 (a.a.520 to 576) | O89811 | 100 µg | 1195 | |
PN0440 | Recombinant Protein-Feline leukemia virus Infection accessory factor (a.a.33 to 273) | Q9J054 | 100 µg | 1195 | |
PN0441 | Recombinant Protein-Feline leukemia virus Env protein (a.a.21 to 412) | Q66988 | 100 µg | 1195 | |
PN0442 | Recombinant Protein-Feline leukemia virus T-cell receptor beta chain T17T-22 (a.a.29 to 321) | P11364 | 100 µg | 1195 | |
PN0443 | Recombinant Protein-Feline leukemia virus VP2 protein (a.a.287 to 504) | Q9QCE2 | 100 µg | 1195 | |
PN0444 | Recombinant Protein-Feline leukemia virus VP3 protein (a.a.505 to 723) | Q9QCE2 | 100 µg | 1195 | |
PN0445 | Recombinant Protein-Feline leukemia virus VP1 protein (a.a.724 to 932) | Q9QCE2 | 100 µg | 1195 | |
PN0446 | Recombinant Protein-Feline leukemia virus 2B protein (a.a.949 to 1136) | Q9QCE2 | 100 µg | 1195 | |
PN0447 | Recombinant Protein-Feline leukemia virus 2C protein (a.a.1136 to 1420) | Q9QCE2 | 100 µg | 1195 | |
PN0448 | Recombinant Protein-Feline leukemia virus 3A protein (a.a.1421 to 1573) | Q9QCE2 | 100 µg | 1195 | |
RPN0435 | cDNA-Feline leukemia virus Envelope protein (a.a.51 to 565) | A8W3S2 | 2 µg | 2570 | |
RPN0436 | cDNA-Feline leukemia virus virion core structural peptide p15 (a.a.75 to 201) | O89811 | 2 µg | 800 | |
RPN0437 | cDNA-Feline leukemia virus virion core structural peptide p12 (a.a.202 to 271) | O89811 | 2 µg | 800 | |
RPN0438 | cDNA-Feline leukemia virus virion core structural peptide p27 (a.a.272 to 519) | O89811 | 2 µg | 1235 | |
RPN0439 | cDNA-Feline leukemia virus virion core structural peptide p10 (a.a.520 to 576) | O89811 | 2 µg | 800 | |
RPN0440 | cDNA-Feline leukemia virus Infection accessory factor (a.a.33 to 273) | Q9J054 | 2 µg | 1200 | |
RPN0441 | cDNA-Feline leukemia virus Env protein (a.a.21 to 412) | Q66988 | 2 µg | 1955 | |
RPN0442 | cDNA-Feline leukemia virus T-cell receptor beta chain T17T-22 (a.a.29 to 321) | P11364 | 2 µg | 1460 | |
RPN0443 | cDNA-Feline leukemia virus VP2 protein (a.a.287 to 504) | Q9QCE2 | 2 µg | 1085 | |
RPN0444 | cDNA-Feline leukemia virus VP3 protein (a.a.505 to 723) | Q9QCE2 | 2 µg | 1090 | |
RPN0445 | cDNA-Feline leukemia virus VP1 protein (a.a.724 to 932) | Q9QCE2 | 2 µg | 1040 | |
RPN0446 | cDNA-Feline leukemia virus 2B protein (a.a.949 to 1136) | Q9QCE2 | 2 µg | 935 | |
RPN0447 | cDNA-Feline leukemia virus 2C protein (a.a.1136 to 1420) | Q9QCE2 | 2 µg | 1420 | |
RPN0448 | cDNA-Feline leukemia virus 3A protein (a.a.1421 to 1573) | Q9QCE2 | 2 µg | 800 |
Feline leukemia virus cDNA and recombinant antigen
Feline leukemia virus (FeLV) is a retrovirus that primarily infects cats. FeLV is the second most common cause of cancer in cats and can also cause a variety of immune-mediated diseases, blood disorders, and other medical problems. The virus is transmitted through close contact with an infected cat, including the sharing of food and water bowls, grooming, and bites. FeLV can cause chronic infections and can be fatal in some cases.
Feline leukemia virus (FeLV) is a retrovirus that infects domestic and wild cats and can cause a variety of diseases including leukemia and immunodeficiency.
The FeLV virion is composed of several structural and functional proteins, including:
Envelope protein – a glycosylated protein that forms the outer layer of the virion and is involved in viral entry into host cells.
P15 – a protein that is involved in the assembly and release of new virus particles.
P12 – a protein that is involved in the regulation of viral gene expression and viral replication.
P27 – a protein that forms the core of the virion and is involved in viral replication and packaging.
P10 – a protein that is involved in the regulation of viral gene expression.
Infection accessory factor – a protein that is involved in the regulation of viral replication and the establishment of persistent infections.
Env protein – a protein that is involved in viral entry into host cells.
T17T-22 – a protein that is involved in viral replication and the regulation of viral gene expression.
VP1, VP2, VP3 – proteins that are involved in the packaging of the viral RNA genome and the formation of the virion.
B2, C2, A3 – proteins that are involved in the regulation of viral gene expression and the establishment of persistent infections.
These proteins work together to allow the virus to infect and replicate within host cells. The envelope protein and Env protein are important for the virus to enter host cells by binding to specific cellular receptors. The P15 and P27 proteins are involved in the assembly and release of new virus particles. The infection accessory factor is involved in the establishment of persistent infections, which can contribute to the development of leukemia and other diseases.
Understanding the function and interactions of these FeLV proteins is crucial for the development of effective diagnostic and therapeutic strategies for FeLV-infected cats. In addition, FeLV is an important model for studying retroviral pathogenesis and evolution, which has implications for human retroviral diseases such as HIV/AIDS.
The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.
Get the Latest News and Updates by Email
6393 Nancy Ridge Dr. Suite A
San Diego, CA 92121 USA
Fax: +1-858-909-0057
Get the Latest News and Updates by Email
© 2023 Bioclone Inc. All Rights Reserved.
Magnetic Beads Make Things Simple